1_phenomeneMassif
π Health and biotech
How science is preparing for antibiotic resistance

The multiple forms of antibiotic resistance

with Agnès Vernet, Science journalist
On March 16th, 2022 |
3min reading time
Philippe Glaser
Philippe Glaser
Research Director in Ecology at Institut Pasteur
Key takeaways
  • Antibiotic resistance occurs when a bacterium survives a dose of antibiotics that would normally kill it.
  • There is a reservoir of genes responsible for antibiotic resistance and a wide variety of biological mechanisms.
  • Antibiotic treatments will select for resistant bacteria and promote the transfer of this ability from one bacterium to another.
  • A better understanding of the mechanisms involved in resistance is essential for developing more effective antibiotics or combinations of treatments.

Anti­bi­ot­ic res­ist­ance is a com­plex prob­lem. It occurs when a bac­teri­um sur­vives a dose of anti­bi­ot­ics that would nor­mally kill it. This concept is thus dir­ectly linked to the way in which the anti­bi­ot­ic molecule acts on the micro-organ­ism and there­fore to how the micro-organ­isms can pro­tect them­selves. There is a wide vari­ety of bac­teria that are poten­tially patho­gen­ic to humans and anim­als, and many dif­fer­ent anti­bi­ot­ic molecules. Under­stand­ing their inter­ac­tions, both at the level of a cell and at the level of a pop­u­la­tion of cells, is essen­tial for under­stand­ing anti­bi­ot­ic resistance.

Molecular shields

There are two types of res­ist­ance: intrins­ic and acquired. The first applies, for example, to bac­teria whose very struc­ture forms a pro­tect­ive lay­er against a tox­ic molecule. Take, for example, van­co­my­cin, an anti­bi­ot­ic that is effect­ive against Sta­phyl­o­coc­cus aure­us or entero­cocci, which are gram-pos­it­ive bac­teria. But for Escheri­chia coli or Pseudo­mo­nas aer­u­ginosa, which are gram-neg­at­ive, this anti­bi­ot­ic does not reach its tar­get. These bac­teria are so-called because they have a double mem­brane that pre­vents the pen­et­ra­tion of the stain developed by the Dan­ish bac­teri­olo­gist Hans Chris­ti­an Gram and thus cer­tain anti­bi­ot­ics. The tar­get of van­co­my­cin is indeed loc­ated between these two mem­branes. Oth­er molecules cap­able of cross­ing the out­er­most mem­brane, such as anti­bi­ot­ics of the peni­cil­lin fam­ily, must there­fore be used against these types of bacteria.

It is acquired anti­bi­ot­ic res­ist­ance that explains the crisis we are cur­rently exper­i­en­cing. It con­cerns micro-organ­isms that were pre­vi­ously sens­it­ive to a molecule to treat an infec­tion and no longer are. Bac­teria have two ways of learn­ing to pro­tect them­selves from a tox­ic molecule. As they divide, they can accu­mu­late muta­tions which, by alter­ing the tar­get of the anti­bi­ot­ic or pre­vent­ing it from enter­ing the cell, render it ineffective.

The second way of acquir­ing res­ist­ance relies on mobile genet­ic ele­ments, i.e. pieces of DNA that can move from one cell to anoth­er. These are usu­ally plas­mids, cir­cu­lar, aux­il­i­ary mini-chro­mo­somes that bac­teria exchange, even between dif­fer­ent spe­cies. These plas­mids are for­mid­able from the point of view of anti­bi­ot­ic res­ist­ance because they can carry sev­er­al genes for res­ist­ance to dif­fer­ent classes of anti­bi­ot­ics. A bac­teri­um can thus become multi-res­ist­ant by the simple acquis­i­tion of such a plasmid.

Bacterial ecology

Plas­mids, and the res­ist­ance genes they carry, are also respons­ible for much of the anti­bi­ot­ic res­ist­ance of the com­mens­al bac­teria of our digest­ive sys­tem. These bac­teria can receive plas­mids con­tain­ing res­ist­ance genes from bac­teria in their envir­on­ment that are less well adap­ted to the gut eco­sys­tem. Res­ist­ance will thus spread among the micro­bi­ota, con­sti­tut­ing a “silent reserve” with clin­ic­al con­sequences that have yet to be evaluated.

The action of an anti­bi­ot­ic depends on the liv­ing con­di­tions of a bac­teri­um, which some­times com­plic­ates the inter­pret­a­tion of labor­at­ory dia­gnoses. A bac­teri­um may be sens­it­ive to an anti­bi­ot­ic in a petri dish, but res­ist­ant in the patient, or vice versa. The action of the treat­ment and the response of the bac­teria vary accord­ing to the envir­on­ment; they will not be identic­al in blood, urine or labor­at­ory con­di­tions. Fur­ther­more, the anti­bi­ot­ic alone can rarely elim­in­ate an infec­tion-caus­ing bac­teri­um because it works with the patient’s immune response. Work, such as our Seq2Diag pro­ject, aims to integ­rate these para­met­ers to improve diagnosis.

The study of res­ist­ance also includes the pop­u­la­tion dynam­ics of bac­teria. Dur­ing an infec­tion, a large num­ber of bac­teri­al cells in dif­fer­ent envir­on­ments are involved and not all are identic­al. Those that are able to sur­vive the admin­istered dose of an anti­obi­ot­ic will take advant­age of the space freed by the sus­cept­ible ones to multiply.

This struggle for space is at the very ori­gin of some anti­bi­ot­ics and res­ist­ance genes. Many anti­bi­ot­ics, such as strep­to­my­cin, used to treat tuber­cu­los­is, have them­selves been isol­ated from bac­teria. Bac­teria pro­duce these molecules to pro­tect their own space and to take over space from the sens­it­ive bac­teria with which they cohab­it. Logic­ally, a bac­teri­um that syn­thes­ises an anti­bi­ot­ic is, in one way or anoth­er, res­ist­ant to that molecule. Anti­bi­ot­ics and res­ist­ance are nat­ur­al phe­nom­ena in the dynam­ics of many bacteria.

Predicting resistance

One of the main ques­tions facing sci­ent­ists today con­cerns the appear­ance of res­ist­ance. Can it be pre­dicted? The prob­lem is com­plex and relies largely on mon­it­or­ing cir­cu­lat­ing strains and ana­lys­ing their genomes. 

This involves com­pil­ing the gen­ome sequences of bac­teria con­sidered to have an atyp­ic­al res­ist­ance pro­file. When the res­ist­ance mech­an­ism is not recog­nised in the gen­ome, bio­lo­gists will try to elu­cid­ate the pro­cess involved and recon­struct its evol­u­tion­ary his­tory. This inform­a­tion could the­or­et­ic­ally help pre­dict the emer­gence of new res­ist­ance. How­ever, new mech­an­isms are rare and are now being detec­ted more quickly. WHO’s GLASS net­work mon­it­ors anti­bi­ot­ic-res­ist­ant bac­teria in low-income coun­tries. As part of the Pri­or­ity Research Plan, the Com­mis­sari­at aux inves­t­isse­ments d’avenir is fund­ing the devel­op­ment of a data­base of bac­teri­al gen­omes linked to anti­bi­ot­ic res­ist­ance. This tool, called ABRom­ics, will bring togeth­er, in a single struc­ture, all the fre­quent and rare res­ist­ances iden­ti­fied in France and will allow to mon­it­or their pro­gress in real time. Such nation­al data­bases are deployed in vari­ous coun­tries. They help to pre­dict the spread of strains that are dif­fi­cult to treat.

Support accurate information rooted in the scientific method.

Donate